Hydroxyzine is NOT Recommended for Anxiety Treatment in a 15-Year-Old
Hydroxyzine should not be used as a first-line or even second-line treatment for anxiety disorders in adolescents. The most recent and authoritative guideline from the American Academy of Child and Adolescent Psychiatry (2020) establishes that cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) are the evidence-based treatments for anxiety in this age group, with no mention of hydroxyzine as a recommended option 1.
Evidence-Based Treatment Hierarchy for Adolescent Anxiety
First-Line Treatment
- CBT should be the initial treatment, particularly for mild-to-moderate anxiety presentations 1
- CBT has "considerable empirical support as safe and effective short-term treatment" 1
Second-Line Treatment
- SSRIs are the pharmacologic alternative, especially for:
- More severe presentations
- When quality CBT is unavailable
- When CBT alone is insufficient 1
Combination Therapy
- CBT + SSRI may be more effective than either treatment alone for short-term outcomes 1
Why Hydroxyzine is Problematic
Lack of Evidence in Adolescents
The available research on hydroxyzine for anxiety has critical limitations:
- Studies were conducted primarily in adults, not adolescents 2, 3
- A Cochrane review concluded hydroxyzine cannot be recommended as "reliable first-line treatment" even in adults due to high risk of bias and small sample sizes 2
- No pediatric-specific efficacy data exists for anxiety treatment
Safety Concerns Specific to Adolescents
The FDA label and recent research highlight serious concerns 4, 5:
Cardiac Risks:
- QT prolongation and Torsade de Pointes reported in post-marketing surveillance
- Requires caution in patients with risk factors for arrhythmias 4
Neurodevelopmental Concerns:
- A 2021 population-based study found repeat hydroxyzine prescriptions in preschool children associated with significantly higher rates of:
- Tic disorders (OR 1.55)
- Anxiety disorders (OR 1.34)
- Conduct disturbances (OR 1.34)
- First study reporting long-term neurodevelopmental adverse effects with early hydroxyzine use 5
CNS Depression:
- Potentiates other CNS depressants
- Causes drowsiness that impairs functioning
- Particular concern in elderly, but adolescents also vulnerable 4
Lack of Guideline Support
The 2020 AACAP guideline comprehensively reviewed anxiety treatments and does not include hydroxyzine among recommended pharmacologic options. The guideline specifically identifies SSRIs and SNRIs as having empirical support, with no mention of antihistamines 1.
Clinical Algorithm for This 15-Year-Old
Step 1: Assess Severity
- Mild-to-moderate anxiety → Start CBT
- Severe anxiety or functional impairment → Consider SSRI or CBT + SSRI
Step 2: If Pharmacotherapy Needed
- First choice: SSRI (e.g., sertraline, fluoxetine)
- Monitor for suicidality, especially in first 4-8 weeks
- Alternative: SNRI if SSRI ineffective or not tolerated
Step 3: Optimize Treatment
- Combine CBT with medication for best outcomes
- Address comorbidities (depression, ADHD common)
Common Pitfalls to Avoid
Using hydroxyzine because it seems "safer" than SSRIs - This is not evidence-based; SSRIs have robust safety and efficacy data in adolescents 1
Prescribing hydroxyzine for "as-needed" anxiety - This provides no treatment of the underlying anxiety disorder and may delay effective intervention
Assuming antihistamine sedation equals anxiety treatment - Sedation is not therapeutic for anxiety disorders and may impair the adolescent's functioning at school
Not considering CBT first - Many providers jump to medication when CBT should be the initial approach for most presentations 1
Bottom Line
For this 15-year-old, initiate CBT as first-line treatment. If pharmacotherapy is warranted due to severity or CBT unavailability, prescribe an SSRI, not hydroxyzine. Hydroxyzine lacks evidence for efficacy in adolescent anxiety, is not recommended by authoritative guidelines, and carries concerning safety signals including potential neurodevelopmental effects and cardiac risks 1, 4, 5.